Boehringer Ingelheim

Pulmonary Fibrosis Foundation's PFF Summit 2023 Advances Research

Retrieved on: 
Thursday, December 7, 2023
Vutrisiran, Extracellular matrix, Genetics, Research, Safety, Food, Travel, ILD, Nursing, Physician, Cystic Fibrosis Foundation, Boehringer Ingelheim, Risk, PFF, PFF Women's League, RN, Patient, Critical care, Virginia Commonwealth University, Medicine, Division, Collaboration, Accreditation, Birmingham School of Law, Caregiver, COVID-19, University, Summit, Vanderbilt University, Nursing care plan, Health care, Doctor of Philosophy, Columbia University, Knowledge, University of Wisconsin–Madison, Pulmonary fibrosis, Critical Care Medicine (journal), Drug development, History of Stanford Medicine, Pharmaceutical industry, Medical device, Certification, MD

CHICAGO, Dec. 7, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's PFF Summit 2023, the world's largest pulmonary fibrosis (PF) and interstitial lung disease (ILD) conference, concluded its seventh biennial meeting on Nov. 11 in Orlando, Fla. Physicians and specialists from around the globe converged to share cutting-edge research, innovative treatment modalities, and real-world clinical experiences in combating PF and ILD. The conference, which took place Nov. 9-11, returned to its in-person format for the first time since 2019.

Key Points: 
  • CHICAGO, Dec. 7, 2023 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's PFF Summit 2023, the world's largest pulmonary fibrosis (PF) and interstitial lung disease (ILD) conference, concluded its seventh biennial meeting on Nov. 11 in Orlando, Fla. Physicians and specialists from around the globe converged to share cutting-edge research, innovative treatment modalities, and real-world clinical experiences in combating PF and ILD.
  • Over three days, the PFF Summit brought together more than 800 healthcare experts, physicians, researchers, patients, caregivers, and industry leaders from 43 states and 16 countries in an exchange of knowledge, experiences, and insights on PF research and care.
  • Recordings from the PFF Summit 2023 will be available on-demand on our YouTube channel in the spring of 2024.
  • The next PFF Summit will be held at the Sheraton Grande Chicago Riverwalk in November 2025.

Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim

Retrieved on: 
Wednesday, December 6, 2023
Boehringer, Boehringer Ingelheim, Life expectancy, ADME, Therapy, Patient, Chemistry, Partnership, Metabolism, Drug discovery, Drug development, Fine chemical

DURHAM, N.C., Dec. 6, 2023 /PRNewswire/ -- Ten63 Therapeutics, a biotechnology company unlocking previously undruggable targets by leveraging proprietary algorithms combining interpretable generative AI and physics-based models, announced today a multi-target drug discovery collaboration with Boehringer Ingelheim. The new partnership is aiming to enable the discovery of novel therapeutic molecules, to address diseases that are out of reach of conventional drug discovery, i.e. diseases with high unmet patient needs.

Key Points: 
  • DURHAM, N.C., Dec. 6, 2023 /PRNewswire/ -- Ten63 Therapeutics, a biotechnology company unlocking previously undruggable targets by leveraging proprietary algorithms combining interpretable generative AI and physics-based models, announced today a multi-target drug discovery collaboration with Boehringer Ingelheim.
  • The new partnership is aiming to enable the discovery of novel therapeutic molecules, to address diseases that are out of reach of conventional drug discovery, i.e.
  • The collaboration will apply Ten63's computational drug discovery engine, BEYOND, to discover novel molecules for multiple Boehringer Ingelheim targets in diverse indications, and leverage Boehringer Ingelheim's expertise in pre-clinical discovery and drug development.
  • The BEYOND platform is composed of a suite of proprietary algorithms designed to enable drug discovery for targets that are difficult for conventional drug discovery technologies.

Ubie's AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships

Retrieved on: 
Monday, December 4, 2023
Pulmonary fibrosis, Synthetic media, Boehringer Ingelheim, Collection, Traction, Patient, Documentation, Health, Lung cancer, Multiple sclerosis, Diagnosis, Press release, Dizziness, Pharmaceutical industry, Medical device, Dietary supplement, Pfizer, Takeda, Audi Q5

NEW YORK, Dec. 4, 2023 /PRNewswire/ -- Ubie, a forerunner in the digital health arena, proudly announces a notable achievement that underscores its commitment to revolutionizing healthcare: Ubie's AI Symptom Checker has been used more than 2 million times in the U.S. since its introduction to the market just over a year ago. This milestone demonstrates the significant traction the tool has gained among individuals eager to better understand and manage their health.

Key Points: 
  • Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year.
  • Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early disease detection and treatment.
  • This milestone demonstrates the significant traction the tool has gained among individuals eager to better understand and manage their health.
  • For more information about Ubie and its AI Symptom Checker, please visit Ubie AI Symptom Checker .

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.

Middle School Students Experience Veterinary Life for a Day with Immersive, Hands-On Learning at World's Largest Veterinary Conference

Retrieved on: 
Tuesday, November 28, 2023
Hyatt Regency Orlando, Pet, Life, Veterinary medicine, Boehringer Ingelheim, Schering-Plough, Labour, Student, Hill, Emergency medicine, Obesity, Animal, Latinx, Hill's Pet Nutrition, CPR, Blood, Trust, Veterinarian, Suture, Partnership, Human, Parent, DEI, Statistics, VMX, Education, Pet industry, Tutoring, Nursing

ORLANDO, Fla., Nov. 28, 2023 /PRNewswire/ -- For the second year, the North American Veterinary Community (NAVC) and nationally-recognized veterinary certification program blendvet will host a full day of hands-on learning for middle school students from underserved communities. The students will learn alongside veterinarians and veterinary nurses/technicians how to examine pets, perform proper animal CPR techniques, suture, and more. The event is in conjunction with the 2024 Veterinary Meeting & Expo (VMX) in Orlando and is sponsored by Boehringer Ingelheim, Hill's Pet Nutrition and Merck Animal Health.

Key Points: 
  • The students will learn alongside veterinarians and veterinary nurses/technicians how to examine pets, perform proper animal CPR techniques, suture, and more.
  • Activities planned for students include:
    Hands-on experience using workshop stations to learn about veterinary surgery, emergency medicine, clinical pathology and preventive care.
  • Educational sessions on various topics related to the different pathways in veterinary medicine and a day in the life of a veterinary professional.
  • Discuss the next steps for students interested in a veterinary career by providing resources to veterinary summer camps, scholarship programs, in-clinic shadowing and more.

Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations

Retrieved on: 
Monday, November 20, 2023
Molecule, Drug metabolism, QC, Boehringer Ingelheim, DMPK, Organization, Partnership, Fine chemical, Pharmacokinetics, Genedata

BASEL, Switzerland, Nov. 20, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Boehringer Ingelheim, one of the largest producers of biopharmaceuticals in the world, has expanded usage of the Genedata platform to include the Drug Metabolism and Pharmacokinetics (DMPK) group in the US. The DMPK US operations use Genedata Biologics® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.

Key Points: 
  • The DMPK US operations use Genedata Biologics ® as part of their life-cycle management strategy of critical reagents (including analytical reference standards and drug products) used in the non-clinical and clinical bioanalytical activities of prospective new biopharmaceutical drugs.
  • We have been using Genedata Biologics across our early biologics discovery operations for many years and are very excited to onboard the US-DMPK group as this is a major step towards having complete end-to-end digital tracking of all BI's therapeutic candidates.
  • "After an initial evaluation, the DMPK group was eager to get onto the Genedata Biologics platform and take advantage of having all information pertaining to critical reagents in one place.
  • One of the strengths of Genedata Biologics is the platform's ability to integrate with Boehringer Ingelheim's laboratory instruments, sample management systems, and corporate IT infrastructure.

CNS Summit Releases Annual Digital Innovation Index

Retrieved on: 
Monday, November 13, 2023
International Innovation Index, Pharma, AstraZeneca, Boehringer Ingelheim, Artificial intelligence, Index, Drug discovery, Roche, AI, Fine chemical, Pharmaceutical industry, Pfizer

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Saturday the CNS Summit Digital Innovation Index, developed in conjunction with IDEA Pharma, was revealed at the CNS Summit.

Key Points: 
  • BOSTON, Nov. 13, 2023 /PRNewswire/ -- Saturday the CNS Summit Digital Innovation Index, developed in conjunction with IDEA Pharma, was revealed at the CNS Summit.
  • The Index evaluates three facets of innovation:
    In 2023, new artificial intelligence (AI) initiatives factored into the Innovation Index rankings.
  • Additional top-ranking firms in the index, including Roche, Boehringer Ingelheim, Pfizer, and others, prioritized strategic collaborations in 2023.
  • CNS Summit's Chairman and Chief Curator, Dr. Amir Kalali, said, "CNS Summit has long fostered and recognized digital and R&D innovation.

Zealand Pharma Announces Financial Results for the First Nine Months of 2023

Retrieved on: 
Thursday, November 9, 2023
DREAM, Short bowel syndrome, FDA, PDUFA, Congenital hyperinsulinism, BMI, Alexion, S&M, Obesity, GIP, Weight loss, KCNA3, G&A, CMC, RCF, MAD, SBS, Zealand Pharma, Chronic kidney disease, CGM, Danske Bank, Hypoglycemia, NASH, Boehringer Ingelheim, Risk, Partnership, EUR, Credit, Part, NDA, Overweight, Patient, Human, Cardiovascular disease, Pharmaceutical industry, Birth control, Fine chemical, CHI, Sanofi

Milestone payments from existing partnerships were recognized in the third quarter of 2023, with cash inflow expected in the fourth quarter of 2023, contributing to the company’s solid financial position.

Key Points: 
  • Milestone payments from existing partnerships were recognized in the third quarter of 2023, with cash inflow expected in the fourth quarter of 2023, contributing to the company’s solid financial position.
  • Boehringer Ingelheim and Zealand Pharma expect to report topline results from the Phase 2 trial with survodutide in NASH in the first half of 2024.
  • In the second half of 2024, Zealand expects topline results from the 13-week dose titration trial.
  • Zealand has completed pre-clinical activities for the Kv1.3 ion channel blocker to support potential first-in-human clinical trials in 2024.

Surrozen Provides Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Research, Patent, Therapy, Workforce, Development, Regeneration, Boehringer Ingelheim, Partnership, Administration, Retina, SAN, Pharmaceutical industry, Cryptocurrency, WNT

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided third quarter 2023 financial results and business updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided third quarter 2023 financial results and business updates.
  • Financial Results for the Third Quarter Ended September 30, 2023
    Cash Position: Cash, cash equivalents and marketable securities were $43.4 million as of September 30, 2023, compared to $53.4 million as of June 30, 2023.
  • General and administrative expenses include non-cash stock-based compensation expenses of $0.7 million for the third quarter ended September 30, 2023 and 2022.
  • Net Loss: Net loss for the third quarter ended September 30, 2023 was $10.4 million, as compared to $13.4 million for the same period in 2022.

IntegriChain Presents The Tina Patel Shining Light Award to Patrick Townsend of Vertex Pharmaceuticals

Retrieved on: 
Tuesday, November 7, 2023
Gene editing, FDA, Janssen, Alexion, Hematology, Partner (business rank), Courage, CRISPR, Conference, Entrepreneurship, Access, Senior, Townsend, Commercialization, Gamer, Boehringer Ingelheim, Paradox Access Solutions, Partnership, Market access, Cystic fibrosis, Service, Vertex Pharmaceuticals, Patient, Alexion Pharmaceuticals, Memory, Pharmaceutical industry, Fine chemical, Management, Vertex

PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced the winners of its annual customer awards today at the Access Insights Conference, co-hosted with Blue Fin Group. IntegriChain presented a new award, The Tina Patel Bright Light Award, to Patrick Townsend, Director of Distribution Strategy, at Vertex Pharmaceuticals. IntegriChain also presented its Commercialization Visionary Award to Johnson & Johnson Innovative Medicine, the Lighthouse Award to Alexion Pharmaceuticals, and the Zero to Launch Award to Tarsus Pharmaceuticals.

Key Points: 
  • IntegriChain presented a new award, The Tina Patel Bright Light Award, to Patrick Townsend , Director of Distribution Strategy, at Vertex Pharmaceuticals .
  • IntegriChain also presented its Commercialization Visionary Award to Johnson & Johnson Innovative Medicine , the Lighthouse Award to Alexion Pharmaceuticals , and the Zero to Launch Award to Tarsus Pharmaceuticals .
  • The Tina Patel Bright Light Award is presented in memory of Tina Patel, Vice President, Market Access Marketing, for Boehringer Ingelheim.
  • The Tinal Patel Shining Light Award: Patrick Townsend, Vertex Pharmaceuticals
    Townsend leads distribution strategy at Vertex.